U.S. Markets close in 3 hrs 49 mins

Lineage Cell Therapeutics, Inc. (LCTX)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
2.7884+0.0484 (+1.77%)
As of 12:10PM EDT. Market open.
Full screen
Loading interactive chart...
  • Lineage's Spinal Cord Injury Cell Therapy Return To Clinical Testing
    Benzinga

    Lineage's Spinal Cord Injury Cell Therapy Return To Clinical Testing

    Following feedback received from the FDA, Lineage Cell Therapeutics Inc (NYSE: LCTX) will submit an amendment to its Investigational New Drug application (IND) for OPC1, allogeneic oligodendrocyte progenitor cell transplant therapy for spinal cord injury (SCI). The IND amendment will be submitted in Q4 of 2021. In February, the Company entered into an exclusive option and license agreement with Neurgain to evaluate its Parenchymal Spinal Delivery (PSD) System in both preclinical and clinical set

  • Lineage Inks Option Agreement With Amasa Therapeutics For HyStem
    Benzinga

    Lineage Inks Option Agreement With Amasa Therapeutics For HyStem

    Lineage Cell Therapeutics Inc (NYSE: LCTX) has granted an exclusive option to Amasa Therapeutics Inc to acquire an exclusive, royalty-bearing license to use its HyStem technology to develop and commercialize therapies for local treatment of solid tumors under pre-negotiated terms. Under the option agreement, Amasa will purchase some amounts of Lineage's existing supply of clinical-grade HyStem biomaterial and has the right to buy additional quantities in up to 12 months. Lineage will receive an